Study of Arginine and Nitric Oxide in Patients With Diabetes
Ketosis Prone Diabetes
About this trial
This is an interventional treatment trial for Ketosis Prone Diabetes
Eligibility Criteria
Inclusion Criteria:
- New onset (defined as receiving a diagnosis within the past 1 year) diagnosis of unprovoked" A-β+ ketosis-prone diabetes
- Aged 20-65 years
- In good health except for diabetes without clinical evidence of micro- or macrovascular complications by history, physical exam and blood chemistries
Exclusion Criteria:
- Chronic or acute illness
- History of myocardial infarction or coronary artery disease or stroke,
- Renal insufficiency (eGFR <90mL/min/1.73m2; <30 mg albumin / g creatinine in urine)
- Abnormal liver, thyroid, gonadal or adrenal functions
- On medications other than metformin,
- On any hormonal replacement therapy
- Pregnancy
Sites / Locations
- Baylor St Lukes Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Citrulline
alanine
In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 20 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 20 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.